Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC monotherapy in HER2-expressing advanced biliary tract cancer after failure of at least first-line chemotherapy
CTR20192057Phase 2Active
- Sponsor
- RemeGen
- Start
- Aug 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in biliary cancer, sponsored by RemeGen. Started Aug 2020; status: active.
02
Drugs
disitamab vedotin
03
Conditions
biliary cancer
Beyond the preview
Go deeper on CTR20192057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192057.